Monopar Therapeutics director Christopher M. Starr disposes of USD 672,243 in common shares

• Director Christopher M. Starr cut his direct stake in Monopar Therapeutics to 5,173 common shares on Oct. 1, 2026.
• Disposed of 8,400 shares via option exercise at $0.005, then sold 8,400 shares at weighted-average prices of $78.09, $78.82, $79.67.
• Also reported 9,880 shares held indirectly through a revocable trust, bringing total beneficial ownership to 15,053 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-032048), on October 05, 2026, and is solely responsible for the information contained therein.